Faster approvals?: Trends in the use of FDA’s expedited approval programs for oncology medications.

Abstract

e18270 Background: With the importance of speed-to-market and addressing unmet needs, pharmaceutical companies have sought accelerated approvals through the Food and Drug Administration (FDA). Introduced with the FDA Safety and Innovation Act (FDASIA) of 2012, Breakthrough Therapy Designation (BTD) has become an important mechanism for approval of serious and life-threatening conditions that do not have adequate therapies. Notably, these pathways have been ill-understood by both pharmaceutical companies and health care providers. This study assessed how BTD and other FDA designations have played a role in the approval of oncology drug marketing applications and evaluated trends in the use of these regulatory pathways. Methods: We analyzed publicly available data on novel oncology drug approvals by the FDA from 2012-2016, including the 4 expedited programs for serious conditions (BTD, Accelerated Approval, Fast Track, and Priority Review). Results: Of the 43 novel oncology drugs approved by the FDA between 2012-2016, 42 used at least 1 of the expedited approval programs, including 65% that used ≥2 programs and 35% that used ≥3 programs. The BTD has been used by 15 of the 43 (35%) approved novel oncology drugs since 2012. The use of the BTD, Accelerated Approval pathway, and Priority Review designation among approved oncology drugs has generally increased each year from 2012-2016, while the use of the Fast Track designation has decreased over the same time period. Conclusions: Companies seeking oncology approvals often use more than one expediting strategy. Alone or in combinations, the BTD, Accelerated Approval, and Priority Review have been shown to play an increasingly important role in oncology drug development. Data collected between 2012-2016 suggest that use of BTD is growing more common, while use of the Fast Track designation has decreased among approved oncology drugs. Additional expedited approval programs have remained steady or increased since the FDA introduced BTD. Based on these observations, we anticipate use of the BTD, Accelerated Approval, and Priority Review designation will grow in future oncology drug applications.

Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010–2019

“…Both the number of products and percentage of annual approvals having at least one expedited designation increased significantly over the decade ( Figure 7A) as did the average number of expedited designations per approval ( Figure 7B). These totals and trends are consistent with those described by others (Hwang et al, 2017;Kesselheim et al, 2015;Vadola et al, 2017). Orphan drug designation is granted to products designed to treat a rare disease or condition, or a subset of a disease or condition, affecting less than 200,000 people in the United States 12 (Boat & Field, 2011).…”

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database

“…T he passage of the US Food and Drug Administration's Breakthrough Designation Act in 2012 and development of targeted therapeutics for patients with cancer have accelerated access to life-prolonging and, in some cases, curative medications, often based on substantial effect sizes seen in smaller, earlier-phase clinical trials. 1 In 2016, the 21st Century Cures Act recognized the need for "real-world evidence" to further establish the benefit of these agents, understand their optimal use, and inform future trial design. 2 Population-based, research-grade, linked clinicogenomic data sets generated from routine clinical care could significantly accelerate the advancement of clinical practice and the development of novel therapeutics.…”